PRESS RELEASE

Biotest increases EBITDA in firsthalf-year by 52% to 8.8 million EUR

• Biotest almost achieves previous year's sales in difficult environment
• Opening of 4 plasma collection centres in the first half of the year
• More plasma centres planned in 2022

Dreieich, 28 July 2022. In the first half of the financial year 2022, the Biotest Group generated sales in the amount of € 253.1 million, which the company believes is more than satisfactory in view of the challenging global economic situation, the coronavirus pandemic and ensuring a sustainable supply of human plasma. The decrease compared to the same period of the previous year of € 257.8 million amounts to 1.8 %.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to € 8.8 million in the first half of the 2022 financial year, compared to € 5.8 million in the first half of the previous year. This corresponds to an increase of 51.7 %.

EBIT in the first half of the year 2022 amounted to € -9.1 million and was thus below the previous year's value of € -8.5 million. In the current year, this includes expenses for the Biotest Next Level project in the amount of € 41.5 million (same period of the previous year: € 38.0 million).

Influenced by a worldwide increase in demand for immunoglobulins, while at the same time the pandemic situation remained difficult, Biotest was able to increase sales, especially of Intratect^®, with an adjusted pricing policy. However, this development could not fully compensate for the decline in sales in the other product areas.

In the reporting period, Biotest AG was already able to open 4 new plasma collection centres. In addition, further new plasma centres are planned in 2022 in order to place the supply of plasma on a broader basis.

Biotest will publish the full figures for the first half of the 2022 financial year on 11 August 2022.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,000 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact

Dr Monika Buttkereit
Phone: 06
E-mail:

PR contact

Dirk Neumüller
Phone: 9
E-mail:

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany,

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.